OMRON-HEALTHCARE
21.1.2022 16:23:07 CET | Business Wire | Press release
OMRON Healthcare , Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S:
- Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE , Residential Systems and TechRadar Pro Picks Awards
- VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection
These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes.
“OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSight was designed to help the 37 million Americans who have uncontrolled Stage 2 hypertension and live every day with a higher risk of heart attack and stroke,” said Andre Van Gils, senior general manager, global sales & marketing and executive officer of OMRON Healthcare Corporation Ltd. - Japan.
Hypertension Plus is designed to help NHS clinicians manage a patient’s medication plan remotely, based on the patient’s home blood pressure results submitted through its dedicated mobile app. The platform generates tailored medication plans for patients, which are then adjusted by clinicians as necessary. Patients are then informed immediately over the dedicated mobile app, connecting them directly to their physician. Automated reminders and scheduled condition management actions keep the patient engaged in treatment. Over time, Hypertension Plus collates the patient’s blood pressure readings along with other key health parameters and informs clinicians when it’s time for their patients to progress in their treatment plan or if there is any urgent action to be taken. All of these recommendations are underpinned by an exclusive algorithm founded on clinically proven medication titration techniques for hypertension, based on current National Institute for Health and Care Excellence (NICE) guidelines, and developed by Oxford university.
In addition to CES, Hypertension Plus has also been recognised by ORCHA (the Organisation for the Review of Care and Health Applications) and Dorset Clinical Commission Group (CCG) on their leading UK-recognised health and care app review portal, with Hypertension Plus currently the highest rated application for hypertension.
In their annual rankings, TWICE, Residential Systems , and TechRadar Pro Picks Awards honor the best and most influential consumer technology. The TWICE Picks Awards Winners 2022 were chosen based on the impact that they are expected to have on the consumer electronic and retail Industries. To see the full list, visit TWICE , Residential Systems or TechRadar Pro .
VitalSight is the first remote patient monitoring service from OMRON Healthcare, an easy-to-use service that a physician can offer to patients with high-risk levels of hypertension. Patients receive a kit delivered to their home that includes an OMRON connected blood pressure monitor and data hub that are pre-set to securely share measurements – digitally – with the patient’s physician and care team. The VitalSight data hub, which can be used at home without Wi-Fi or cellular connection, received attention at CES for bridging health care gaps for patients in under-resourced communities.
Insider recognised VitalSight by OMRON on its list of 13 most exciting health, home and kitchen products of CES 2022. The list brought together high-tech concepts and new products – unveiled at CES 2022 – that you can buy now or later in 2022. Insider cited VitalSight among the “Best of” CES as “life-saving technology” and “great technology for patients who can't see their doctor regularly because of location, finances, or mobility concerns.” To see the full list, visit Insider.
“Our team, fully committed to our Going for Zero mission, worked diligently to create and launch our remote patient monitoring services around the world,” said Van Gils. “We are fortunate to have such dedicated staff and employees who are passionate about empowering people to take charge of their heart health and saving lives. Congratulations to our team on this extraordinary effort.”
To learn more about Remote Patient Monitoring services from OMRON, visit: https://healthcare.omron.com/ces2022
To learn more about OMRON Healthcare, the company’s Going for Zero mission and its innovations, visit omron-healthcare.co.uk , and follow OMRON Healthcare on Twitter and LinkedIn.
About OMRON Healthcare
Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.
Throughout its 85-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.
OMRON Healthcare is the Global No.1 brand in both blood pressure monitors, with over 200 million units sold, as well as nebulizers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.
OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom